Header

UZH-Logo

Maintenance Infos

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial


Weller, Michael; Butowski, Nicholas; Tran, David D; Recht, Lawrence D; Lim, Michael; Hirte, Hal; Ashby, Lynn; Mechtler, Laszlo; Goldlust, Samuel A; Iwamoto, Fabio; Drappatz, Jan; O'Rourke, Donald M; Wong, Mark; Hamilton, Mark G; Finocchiaro, Gaetano; Perry, James; Wick, Wolfgang; Green, Jennifer; He, Yi; Turner, Christopher D; Yellin, Michael J; Keler, Tibor; Davis, Thomas A; Stupp, Roger; Sampson, John H; ACT IV trial investigators, (2017). Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncology, 18(10):1373-1385.

Statistics

Citations

Dimensions.ai Metrics
136 citations in Web of Science®
135 citations in Scopus®
60 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

355 downloads since deposited on 15 Nov 2017
354 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:October 2017
Deposited On:15 Nov 2017 14:36
Last Modified:06 Oct 2019 05:48
Publisher:Elsevier
ISSN:1470-2045
OA Status:Green
Publisher DOI:https://doi.org/10.1016/S1470-2045(17)30517-X
PubMed ID:28844499

Download

Download PDF  'Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 1MB
View at publisher
Licence: Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)